Targeting KRAS4A splicing through the RBM39/DCAF15 pathway inhibits cancer stem cells.

Nat Commun · 2021 · PMC8277813 · PMID 34257283

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

highly significantno p-value reported

Highly significant increases in both KRAS4A and KRAS4B transcripts were found in RNAseq data from KRAS mutant versus WT lung adenocarcinoma (LUAD) tumors, but KRAS4A showed a greater fold increase (1.7) than KRAS4B (1.2) (Supplementary Fig. 9A–C ).

also in 132,142 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.